Fig. 2 | npj Breast Cancer

Fig. 2

From: SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

Fig. 2

SETER/PR and patient survival. SETER/PR and progression-free and overall survival in patients with HR+/HER2 metastatic breast cancer. Kaplan−Meier curves are shown for progression-free a and overall survival b in patients that presented with relapsed stage IV breast cancer and received endocrine therapy as next treatment and for the clinically relevant subgroup of patients with a prior history of sensitivity to adjuvant or metastatic endocrine treatment c, d

Back to article page